Iron overload in β-thalassemia intermedia: An emerging concern

Current Opinion in Hematology

Volumn 20, Issue 3, 2013, Pages 187-192

  Musallam, Khaled M ^a,b   Cappellini, Maria D ^a   Taher, Ali T ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

assessment; liver iron concentration; management; morbidity

Indexed keywords

DEFERASIROX; FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; IRON; IRON CHELATING AGENT; PLACEBO;

ADVERSE OUTCOME; BETA THALASSEMIA; CARDIOVASCULAR MAGNETIC RESONANCE; CROSS-SECTIONAL STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HUMAN; HYPOTHYROIDISM; INTESTINE ABSORPTION; IRON OVERLOAD; KIDNEY TUBULE DISORDER; LIVER CELL CARCINOMA; LIVER LEVEL; MORBIDITY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK FACTOR;

BETA-THALASSEMIA; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD;

EID: 84876298371     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32835f5a5c     Document Type: Review

References (33)

1. Musallam KM, Taher AT, Rachmilewitz EA. beta-Thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med 2012; 2:a013482.
2. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115:1886-1892.
3. Ginzburg Y, Rivella S. beta-Thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011; 118:4321-4330.
4. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in nontransfusion-dependent thalassemia: a clinical perspective. Blood Rev 2012; 26 (Suppl 1):S16-19.
5. Nai A, Pagani A, Mandelli G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood 2012; 119:5021-5029.
6. Parrow NL, Gardenghi S, Ramos P, et al. Decreased hepcidin expression in murine beta-thalassemia is associated with suppression of Bmp/Smad signaling. Blood 2012; 119:3187-3189.
7. Casanovas G, Vujic Spasic M, Casu C, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 2012. 10.3324/haematol.2012.069807. [Epub ahead of print]
8. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007; 92:583-588. (Pubitemid 350144260)
9. Taher A, Musallam KM, El Rassi F, et al. Levels of nontransferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 2009; 146:569-572.
10. Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012; 120:970-977.
11. Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 2010; 150:486-489.
12. Taher A, El Rassi F, Isma'eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008; 93:1584-1586.
13. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica 2011; 96:1605-1612.
14. Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 2007; 49:329-332. (Pubitemid 47236225)
15. Musallam KM, Motta I, Salvatori M, et al. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with beta-thalassemia intermedia. Blood Cells Mol Dis 2012; 49:136-139.
16. Maakaron JE, Cappellini MD, Graziadei G, et al. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. Ann Hepatol 2013; 12:142-146.
17. Musallam KM, Cappellini MD, Daar S, et al. Serum ferritin levels and morbidity in b-thalassemia intermedia: a 10-year cohort study [abstract]. Blood 2012; 120:1021.
18. Ziyadeh FN, Musallam KM, Mallat NS, et al. Glomerular hyperfiltration and proteinuria in transfusion-independent patients with beta-thalassemia intermedia. Nephron Clin Pract 2012; 121:c136-c143.
19. Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in beta-thalassemia intermedia: breaking the silence. Thromb Res 2012; 130:695-702.
20. Musallam KM, Beydoun A, Hourani R, et al. Brain magnetic resonance angiography in splenectomized adults with beta-thalassemia intermedia. Eur J Haematol 2011; 87:539-546.
21. Musallam KM, Nasreddine W, Beydoun A, et al. Brain positron emission tomography in splenectomized adults with beta-thalassemia intermedia: uncovering yet another covert abnormality. Ann Hematol 2012; 91:235-241.
22. Musallam KM, Taher AT. Thrombosis in thalassemia: why are we so concerned? Hemoglobin 2011; 35:503-510.
23. Rivella S. The role of ineffective erythropoiesis in nontransfusion- dependent thalassemia. Blood Rev 2012; 26 (Suppl 1):S12-15.
24. Wood JC. Impact of iron assessment by MRI. Hematol Am Soc Hematol Educ Program 2011; 2011:443-450.
25. Taher AT, Musallam KM, Wood JC, Cappellini MD. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol 2010; 85:288-290.
26. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Contemporary approaches to treatment of beta-thalassemia intermedia. Br J Haematol 2011; 152:512-523.
27. Taher A, Porter J, Viprakasit V, et al. Reduction in liver iron concentration is consistent across subgroups of nontransfusion-dependent thalassemia patients treated with deferasirox: results from the 1-year THALASSA study [abstract]. Haematologica 2012; 96:0924.
28. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox continues to reduce iron overload in nontransfusion-dependent thalassemia: a one-year, open-label extension to a one-year, randomized, double-blind, placebo-controlled study (THALASSA) [abstract]. Blood 2012; 120:3258.
29. Taher A, Porter J, Viprakasit V, et al. Estimation of liver iron concentration by serum ferritin measurement in nontransfusion-dependent thalassemia patients: analysis from the 1-year THALASSA study [abstract]. Haematologica 2012; 96:0927.
30. Musallam KM, Cappellini MD, Taher AT. Evaluation of the 5 mg/g liver iron concentration threshold and its association with vascular and endocrine/bone morbidity in b-thalassemia intermedia [abstract]. Blood 2012; 120:1024.
31. Karimi M, Musallam KM, Cappellini MD, et al. Risk factors for pulmonary hypertension in patients with beta thalassemia intermedia. Eur J Intern Med 2011; 22:607-610.
32. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest 2010; 120:4466-4477.
33. Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010; 16:177-182.